|
Phenocure's commercial strategy will be focused in generating revenue
from 3 main areas:
1. PFR based partnerships
Partnership based licensing and collaborations with leading Pharmaceutical
companies to apply PFR based Drug discovery technologies in key
high-need therapeutic areas, alternative to gene therapy.
2. PhenoCure's internal
Drug pipeline
PhenoCure has applied PFR technologies to discover a drug compound
- CC1 - which is a potential cure for Bone and Colon cancers. PhenoCure
intends to apply PFR discovery technologies to other high need therapeutic
areas.
3. Foldase based partnerships
and projects - functional proteins and associated technologies
Partnership based licensing and collaborations with leading Pharmaceutical
companies to apply Foldase protein expression technologies to enhance
and accelerate protein expression stages within the drug discovery
process.
The commercial and Research & Development
activities of PhenoCure will result in the company building value
by consolidating existing proprietary technologies and therapeutics,
developing further therapeutics and by making further technical
advances to simultaneously grow its short, medium, and long term
revenue streams.
|